ContraFect (CFRX) Prices 11.797M Share & Warrants Offering at $4.90/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures steady as oil jumps to two-week high ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- Houthi strike on Saudi airport kills 12, worst attack on kingdom in a decade
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake shakes nation, but avoids major destruction
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
May 21, 2020 10:59 PM EDTYONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced the pricing of its underwritten public offering of 11,797,752 shares of its common stock and related warrants to purchase 8,848,314 shares of common stock with an exercise price of $4.90 per share, in exchange for consideration equating to $4.45 for one share of common stock and a warrant to purchase 0.75 shares of common stock. The gross proceeds from the public offering will be approximately $52.5 million,... More



